https://orcid.org/0000-0003-3243-8018
References
- Rutter WC , BurgessDR , BurgessDS. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. Microb. Drug Resist.23(1), 51–55 (2017).
- Vasiljevic ZV , NovovicK , KojicMet al. Burkholderia cepacia complex in serbian patients with cystic fibrosis: prevalence and molecular epidemiology. Eur. J. Clin. Microbiol. Infect. Dis.35(8), 1277–1284 (2016).
- Farfour E , TrochuE , DevinCet al. Trends in ceftazidime–avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients. Transpl. Infect. Dis.20(5), e12955 (2018).
- Massip C , MathieuC , GaudruCet al. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. J. Antimicrob. Chemother.74(2), 525–528 (2019).
- Bonacorsi S , FitoussiF , LhopitalSet al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother.43(2), 213–217 (1999).
- Lomovskaya O , SunD , Rubio-AparicioDet al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother.61(11), 17–32 (2017).
- Tsivkovski R , LomovskayaaO. Biochemical activity of vaborbactam. Antimicrob. Agents Chemother.64(2), 19–27 (2020).
- Wunderink RG , Giamarellos-BourboulisEJ , RahavGet al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect. Dis. Ther.7(4), 439–455 (2018).
- Romanelli F , StolfaS , MoreaAet al. Meropenem–vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment. Future Microbiol.16(16), 1261–1266 (2021).
- Bassetti M , PecoriD , CojuttiPet al. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin. Drug Metab. Toxicol.13(11), 1193–1200 (2017).
- European Committee on Antimicrobial Susceptibility Testing . Breakpoint tables for interpretation of MICs and zone diameters version 11.0 (2021). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf
- Clinical and laboratory Standard Institute (2020). https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf
- Pogue JM , BonomoRA , KayeKS. Ceftazidime/avibactam, meropenem–vaborbactam, or both? Clinical and formulary considerations. Clin. Infect. Dis.68(3), 519–524 (2019).
- Caverly LJ , SpilkerT , KalikinLMet al. In vitro activities of β-lactam-β-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens. Antimicrob. Agents Chemother.64(1), 19–22 (2020).
- Moriceau C , EveillardM , LemariéC , ChenouardR , PailhorièsH , KempfM. Stenotrophomonas maltophilia susceptibility to ceftazidime–avibactam combination versus ceftazidime alone. Med. Mal. Infect.50(3), 305–307 (2020).
- Biagi M , TanX , WuTet al. Activity of potential alternative treatment agents for Stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim–sulfamethoxazole. J. Clin. Microbiol.58(2), 9–18 (2020).
- Ruppé É , WoertherP-L , BarbierF. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann. Intensive Care5(1), 61 (2015).
- Rhodes KA , SchweizerHP. Antibiotic resistance in Burkholderia species. Drug Resist. Updat.28, 82–90 (2016).
- Abbott IJ , PelegAY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin. Respir. Crit. Care Med.36(1), 99–110 (2015).
- European Committee on Antimicrobial Susceptibility Testing . Stenotrophomonas maltophilia (2012). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/S_maltophilia_EUCAST_guidance_note_20120201.pdf
- European Committee on Antimicrobial Susceptibility Testing . Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC) (2013). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/BCC_susceptibility_testing_130719.pdf
- Wootton M , DaviesL , PitmanK , HoweRA. Evaluation of susceptibility testing methods for Burkholderia cepacia complex: a comparison of broth microdilution, agar dilution, gradient strip and EUCAST disc diffusion. Clin. Microbiol. Infect.27(5), 788.e1–788.e4 (2021).
- Sfeir MM . Antimicrobial susceptibility testing for glucose-nonfermenting Gram-negative bacteria: the tip of the iceberg. Antimicrob. Agents Chemother.64(4), 1–2 (2020).